Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
4.54M
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
25.9M
-
Shares change
-
+16.3M
-
Total reported value, excl. options
-
$1.26B
-
Value change
-
+$803M
-
Put/Call ratio
-
2.41
-
Number of buys
-
95
-
Number of sells
-
-14
-
Price
-
$48.71
Significant Holders of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) as of Q2 2025
129 filings reported holding CDTX - Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2025.
Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) has 106 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.9M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (3.37M shares), Bain Capital Life Sciences Investors, LLC (2.5M shares), Point72 Asset Management, L.P. (1.53M shares), Vivo Capital, LLC (1.31M shares), Commodore Capital LP (1.18M shares), BlackRock, Inc. (1.11M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.1M shares), TCG Crossover Management, LLC (1.01M shares), VANGUARD GROUP INC (967K shares), and MORGAN STANLEY (883K shares).
This table shows the top 106 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.